Fast Money friend Carl Icahn is shaking things up again this time with an unprecedented offer extended to CIT’s small bondholders. And he revealed his entire strategy to us! Read More
Warren Buffett is one of twenty-seven business, government, and academic leaders endorsing what's described as a "bold call to end the focus on value-destroying short-termism" in financial markets. A new statement from the Aspen Institute argues that shareholders are playing a key role by pushing corporations for short-term stock price gains at the expense of long-term sustainability. Read More
After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next. Read More
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer. Read More
Before I give you the high-tension, high-drama, high-intrigue details of the Biogen Idec shareholder meeting, it's best to just right from the get-go to let you know a spokesperson for the biotech company said, "No comment," about what's going down. Read More
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month. Read More
It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting. Read More
Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders. Read More